NeoPharm CO., LTD. (KOSDAQ: 092730)

Market Cap	172.22B
Revenue (ttm)	112.20B
Net Income (ttm)	22.33B
Shares Out	15.25M
EPS (ttm)	1,427.89
PE Ratio	7.91
Forward PE	6.69
Dividend	375.00 (3.32%)
Ex-Dividend Date	Dec 27, 2024

Volume	67,364
Average Volume	57,790
Open	11,070
Previous Close	11,150
Day's Range	11,070 - 11,480
52-Week Range	11,000 - 34,300
Beta	0.79
RSI	38.69
Earnings Date	Feb 7, 2025

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 177
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092730

Financial Performance

In 2023, NeoPharm CO., LTD.'s revenue was 97.10 billion, an increase of 14.20% compared to the previous year's 85.03 billion. Earnings were 23.21 billion, an increase of 36.33%.